Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $21.25 in the prior trading day, Vera Therapeutics Inc (NASDAQ: VERA) closed at $21.01, down -1.13%. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 0.54 million shares were traded.
Ratios:
Our goal is to gain a better understanding of VERA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 27.30 and its Current Ratio is at 27.30. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.
On January 28, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $58.Goldman initiated its Buy rating on January 28, 2025, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’25 when Fordyce Marshall sold 10,613 shares for $27.89 per share. The transaction valued at 296,032 led to the insider holds 213,740 shares of the business.
Fordyce Marshall sold 9,075 shares of VERA for $250,882 on Feb 26 ’25. The PRESIDENT AND CEO now owns 204,665 shares after completing the transaction at $27.65 per share. On Feb 26 ’25, another insider, MARSHALL FORDYCE, who serves as the Director of the company, bought 9,075 shares for $27.10 each.
Stock Price History:
Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -11.69%, while the 200-Day Moving Average is calculated to be -41.29%.
Shares Statistics:
A total of 63.77M shares are outstanding, with a floating share count of 48.07M. Insiders hold about 23.13% of the company’s shares, while institutions hold 90.06% stake in the company.
